Tower Wealth Partners’s AbbVie ABBV Stock Holding History

Tower Wealth Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$346K	Buy	1,593 +1	+0.1%	+$222	0.19%	57
2025 Q4	$364K	Buy	1,592 +23	+1%	+$5.24K	0.2%	55
2025 Q3	$363K	Buy	1,569 +32	+2%	+$6.52K	0.2%	56
2025 Q2	$285K	Buy	1,537 +51	+3%	+$9.48K	0.17%	62
2025 Q1	$311K	Buy	1,486 +73	+5%	+$14.2K	0.17%	54
2024 Q4	$251K	Sell	1,413 -13	-0.9%	-$2.39K	0.13%	60
2024 Q3	$282K	Buy	1,426 +11	+0.8%	+$2.05K	0.16%	53
2024 Q2	$243K	Buy	1,415 +195	+16%	+$32.3K	0.15%	56
2024 Q1	$222K	Buy	+1,220	New	+$210K	0.14%	56

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tower Wealth Partners's ABBV Position: Q1 2026 in Review

Tower Wealth Partners increased its AbbVie (ABBV) stake by 0.06% in Q1 2026, buying an estimated $222 and bringing the position to 1,593 shares worth $346K. The position accounts for 0.19% of the portfolio, ranked #57.

Tower Wealth Partners first reported a position in ABBV in Q1 2024 and has held it in 9 quarters since. The position peaked at $364K in Q4 2025. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Tower Wealth Partners held 1,593 shares of AbbVie worth $346K as of Q1 2026.
Tower Wealth Partners bought 1 AbbVie share in Q1 2026, an estimated $222.
AbbVie made up 0.19% of Tower Wealth Partners's portfolio in Q1 2026, its #57 holding.
Tower Wealth Partners first reported a position in AbbVie in Q1 2024 and has held it in 9 quarters since.
Tower Wealth Partners's AbbVie position peaked at $364K in Q4 2025.
4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Tower Wealth Partners's 13F filing for Q1 2026, filed 8 May 2026.